Navigation Links
Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
Date:12/9/2010

lood vessel growth and cell metabolism.

In the US, everolimus is available in different dosage strengths under the trade name Zortress® for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving a kidney transplant. In the EU, everolimus is available in different dosage strengths under the trade name Certican® for the prevention of organ rejection in heart and kidney transplant recipients.

Everolimus is exclusively licensed for use in drug-eluting stents to Abbott for the XIENCE V® and XIENCE PRIME™ Everolimus Eluting Coronary Stent System*, and sublicensed to Boston Scientific for the PROMUS™ and PROMUS™ Element™ Everolimus Eluting Coronary Stent System**.

Not all indications are available in every country. As an investigational compound the safety and efficacy profile of everolimus has not yet been established in breast cancer. Access to everolimus outside of the approved indications has been carefully controlled and monitored in clinical trials designed to better understand the potential benefits and risks of the compound. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will become commercially available for breast cancer or any additional indications anywhere in the world.

Important Safety Information About Afinitor (everolimus) tablets Patients should not take Afinitor if they are allergic to Afinitor or to any of its ingredients. Patients should tell their healthcare provider before taking Afinitor if they are allergic to sirolimus (Rapamune®) or temsirolimus (Torisel®).

Afinitor can cause serious side effects including infections or lung or breathing problems.

Afinitor may make patients more likely to develop an infection, such as pneumonia, or a bacterial, fungal or viral infection. Viral infections may include reactivation of hepatitis B in people who have had hepatitis B in the past. I
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013 China Biologic Products, Inc. ... fully integrated plasma-based biopharmaceutical company in China ... learned from a public announcement issued by Shanghai RAAS ... listed on Shenzhen Stock Exchange, that on May 21, ... ("Ms. Chan"), one of the shareholders of the Company, ...
(Date:5/24/2013)... , May 24, 2013 In accordance with Rule ... Rule 14e-1 of the United States Exchange Act, Echo Pharma ... offer for Elan Corporation (NYSE: ELN). Background ... Pharma") made an offer for the entire of the issued ... ("Elan") (the "Original Offer").  On 20 May ...
(Date:5/24/2013)... -- The potential of the pulmonary route ... agents has been receiving undeniable attention with the recent ... The crucial formulation considerations for orally inhaled products together ... role in the efficiency of pulmonary delivery, and great ... formulation techniques and devices in recent years. ...
Breaking Medicine Technology:China Biologic Comments on the Proposed Shanghai RAAS Transaction 2China Biologic Comments on the Proposed Shanghai RAAS Transaction 3China Biologic Comments on the Proposed Shanghai RAAS Transaction 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 2Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 3Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 4Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 5Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 6Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 7Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 8Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements 9Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2
... Mass. and SYDNEY, April 15, 2011 HeartWare ... HIN), a leading innovator of less invasive, miniaturized ... of advanced heart failure, today announced the presentation ... heart transplantation (BTT) study, ADVANCE, showing 180-day survival, ...
... Nanotechnologies, Inc. ("Shrink") (OTCBB:INKN), an innovative high technology ... Shrink,s Cell Align™ cell culturing and tissue engineering ... substrate has been filed with the US Patent ... a micro-fabricated substrate with non-periodic (or random) linear ...
Cached Medicine Technology:HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 2HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 3HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 4HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients 5Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO 2Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO 3
(Date:5/24/2013)... Los Angeles, CA (PRWEB) May 24, 2013 ... “Looking Good on Facebook: Social Media Leads to Spikes in ... indicate that there is a growing prevalence of facial ... utilize social media. These people have become keenly aware of ... profiles on sites such as Facebook, Google and even Skype's ...
(Date:5/24/2013)... FRIDAY, May 24 (HealthDay News) -- The number ... units after spending time in an emergency room ... new research. The study, conducted by researchers ... Health and Health Services in Washington, D.C., found ... room on average before being admitted to the ...
(Date:5/24/2013)... fractional flow reserve (FFR) using pressure wire assessment ... leads to significant changes in the management of ... a study reported at EuroPCR 2013. , The ... strategy at coronary angiography for diagnosis of chest ... assessment of FFR in all the main coronary ...
(Date:5/24/2013)... Ore. A new discovery at Oregon Health & ... body effectively reacts when infected with the highly evasive ... researchers has been utilizing this unique approach to develop ... shown promising results in animal studies. This latest research ... edition of the journal Science . , ...
(Date:5/24/2013)... CBT News.com recently announced the addition of Tom Gonter as ... news organization with 12 years experience in online and social ... that’s so forward-thinking in their approach,” says Gonter. “CBT News ... on the rise.” , Atlanta born and raised, Gonter began ... at Cycle News and Boating World. He made the move ...
Breaking Medicine News(10 mins):Health News:Facebook and Google – Is Social Media Driving Demand for Plastic Surgery? 2Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2
... , ... , an Australian start-up, has been selected to showcase its revolutionary service for managing ... ... Global financial innovation conference, Finovate, has selected Controlabill to showcase its revolutionary service for ...
... ... accreditation by COLA, a national healthcare accreditation organization. , ... (PRWEB) March 24, 2010 -- This year, US ... performance in quality patient testing and overall exemplary application of the principles of laboratory ...
... The ... But, what most of us don’t know is that chemotherapy wreaks havoc on our teeth ... with your dental health while undergoing chemotherapy and radiation. , ... (PRWEB) March 24, 2010 -- Steven McConnell - a Marin ...
... , ... will be presenting three sessions in April to increase awareness in the U.S. about the ... can increase early detection and prevention. , ... New York, NY (Vocus) March 24, 2010 -- The Bella Moss Foundation, a ...
... , ... Many of seniors, greatest fears are tied to the loss ... to remain active because of conditions that often accompany aging. But staying ... Paul Hogan. In response to mounting research that underscores the mental and ...
... ... ... -- At just over 18 pounds and with a sound level of only 58 dBA, ... quieter than its battery-operated competitors. Powered by a lithium ion battery with 30 minutes of ...
Cached Medicine News:Health News:Global Financial Innovations Conference Chooses Australian Start Up, Controlabill 2Health News:US Wellness, Inc. Receives National Recognition for Laboratory Excellence 2Health News:Recommended Dental Care for Chemotherapy Patients -- Advice from Steven McConnell, DDS 2Health News:Recommended Dental Care for Chemotherapy Patients -- Advice from Steven McConnell, DDS 3Health News:The Bella Moss Foundation Announces U.S. Tour to Raise Awareness of MRSA in Pets 2Health News:The Bella Moss Foundation Announces U.S. Tour to Raise Awareness of MRSA in Pets 3Health News:Senior Fear Factors: What Aging Americans Fear Most 2Health News:Senior Fear Factors: What Aging Americans Fear Most 3Health News:Advance Introduces the Adgility™ XPB Battery Backpack Vacuum – the Lightest in the Industry, 2
This set offers the full range of Keeler magnifiers and telescopes....
... Featuring up to ... allows examination in the ... sections plus the option ... for corneal transillumination., ,Filters ...
... image guided surgery system offers full-featured ... design and use. It provides unparalleled ... localize critical anatomy and plan optimal ... surgeons an easy-to-use, technologically advanced approach ...
Comes complete with its own case. A unique integrated design with no need for two separate bars., ,Optical surfaces are recessed for optimum protection. Extensive prism power 1,2,3,4,6,8,10,15,20...
Medicine Products: